Please use this identifier to cite or link to this item:
|Title:||Valacyclovir for herpes simplex encephalitis|
Julie Nguyen Pouplin
Pham Van Toi
H. Rogier Van Doorn
Tran Tinh Hien
M. Estée Török
Tran Thi Hong Chau
Cambridge University Hospitals NHS Foundation Trust
|Keywords:||Medicine;Pharmacology, Toxicology and Pharmaceutics|
|Citation:||Antimicrobial Agents and Chemotherapy. Vol.55, No.7 (2011), 3624-3626|
|Abstract:||The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings. Copyright © 2011, American Society for Microbiology. All Rights Reserved.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.